EVS Glaucoma Therapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $50K
Latest Deal Amount
  • Investors
  • 1

EVS Glaucoma Therapeutics General Information

Description

Developer of a biodegradable drug delivery system designed to be used for glaucoma medication. The company's bio-degradable drug delivery system develops an implantable, bio-degradable, collagen-based system for Latanoprost, enabling targeted patients to avail premium drugs for better outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2810 Towerview Road
  • Herndon, VA 20171
  • United States
+1 (800) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

EVS Glaucoma Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 11-Sep-2013 $50K 0000 Completed Startup
To view EVS Glaucoma Therapeutics’s complete valuation and funding history, request access »

EVS Glaucoma Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Michael Ross Chief Executive Officer & Chairman
To view EVS Glaucoma Therapeutics’s complete executive team members history, request access »

EVS Glaucoma Therapeutics Board Members (1)

Name Representing Role Since
Michael Ross EVS Glaucoma Therapeutics Chief Executive Officer & Chairman 000 0000
To view EVS Glaucoma Therapeutics’s complete board members history, request access »

EVS Glaucoma Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Center for Innovative Technology Venture Capital Minority 000 0000 000000 0
To view EVS Glaucoma Therapeutics’s complete investors history, request access »